Sales Agreement Sample Contracts

Class a Common Stock ($0.01 Par Value Per Share) Capital on Demand Sales Agreement (August 10th, 2018)
Tier Reit Inc – Tier Reit, Inc. Up to $125,000,000 Shares of Common Stock Controlled Equity Offering Sales Agreement (August 8th, 2018)

TIER REIT, Inc., a Maryland corporation (the Company), and Tier Operating Partnership LP, a Texas limited partnership and the Companys operating partnership (the Operating Partnership), confirm their agreement (this Agreement) with [ ] (the Agent), as follows:

Amendment No. 1 to Common Stock Sales Agreement (August 2nd, 2018)

Caladrius Biosciences, Inc. (the "Company") and H.C. Wainwright & Co. LLC ("HCW") are parties to that certain Common Stock Sales Agreement dated February 8, 2018 (the "Original Agreement"). All capitalized terms not defined herein shall have the meanings ascribed to them in the Original Agreement. The parties, intending to be legally bound, hereby amend the Original Agreement as follows:

America First Tax Exempt Investors, L.P. – Capital on Demand Sales Agreement (August 1st, 2018)
Atm Equity Offeringsm Sales Agreement (August 1st, 2018)

Ventas, Inc., a Delaware corporation (the Company), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time to or through any of Merrill Lynch, Pierce, Fenner & Smith Incorporated, Citigroup Global Markets Inc., Credit Agricole Securities (USA) Inc., J.P. Morgan Securities LLC, Morgan Stanley & Co. LLC, MUFG Securities Americas Inc., RBC Capital Markets, LLC, UBS Securities LLC and Wells Fargo Securities, LLC, as sales agent and/or principal (each, an Agent, and collectively, the Agents), shares (the Shares) of the Companys common stock, $0.25 par value (the Common Stock), having an aggregate gross sales price not to exceed $1,000,000,000. The Company agrees that whenever it determines to sell Shares directly to an Agent as principal it will enter into a separate written Terms Agreement (each, a Terms Agreement), in substantially the form of Annex I hereto, relating to such sale in accordance with Section 2(k) hereof. References herein to this

CytoSorbents Corporation Controlled Equity OfferingSM Amendment No. 1 to Sales Agreement (July 26th, 2018)
Plasaver – Myos Rens Technology Inc. Common Stock Sales Agreement (July 24th, 2018)
Xenon Pharmaceuticals Inc. – XENON PHARMACEUTICALS INC. Common Shares AT-THE-MARKET EQUITY OFFERING SALES AGREEMENT (July 12th, 2018)
Amendment No. 1 to Common Stock Sales Agreement (June 29th, 2018)

Savara, Inc. (the Company) and H.C. Wainwright & Co. LLC (HCW) are parties to that certain Common Stock Sales Agreement dated April 28, 2017 (the Original Agreement). All capitalized terms not defined herein shall have the meanings ascribed to them in the Original Agreement. The parties, intending to be legally bound, hereby amend the Original Agreement as follows:

Probe Manufacturing – This Reciprocal Sales Agreement Agreement Is Entered Into on the 23rd May 2018 Between the Parties as Defined Below: Parties Biomass Power Ltd (BPL) With Its Registered Office At: Lichfield Road, Stafford, ST17 4BQ Registered in the United Kingdom With Company No. 06340386 and Clean Energy Technologies, Inc (CETY) With Its Registered Office At: 2990 Redhill Avenue Costa Mesa, California 92626 Registered in the United States of America as a Nevada Corporation. WHEREAS: BPL and CETY the Parties Agree to Actively Promote the Sale of the Following Products: - BPL HORC - 140, BPL HORC - 280, BPL HO (June 22nd, 2018)

and may from time to time refer potential customers to the each other to place orders. It is agreed that no monies shall be exchanged for any lead or order placement between the Parties.

Axovant Sciences Ltd. – Axovant Sciences Ltd. Common Shares Sales Agreement (June 22nd, 2018)
Trevena Inc – Trevena, Inc. Up to $50,000,000 of Shares Common Stock Sales Agreement (June 15th, 2018)
Cohbar, Inc. – COHBAR, INC. Shares of Common Stock (Par Value $0.001 Per Share) Controlled Equity OfferingSM Sales Agreement (June 12th, 2018)
Kilroy Realty, L.P. – Kilroy Realty Corporation Sales Agreement (June 5th, 2018)

Kilroy Realty Corporation, a Maryland corporation (the Company) and Kilroy Realty, L.P., a Delaware limited partnership (the Operating Partnership), confirm their agreement with Merrill Lynch, Pierce, Fenner & Smith Incorporated, Citigroup Global Markets Inc., Jefferies LLC, J.P. Morgan Securities LLC, Raymond James & Associates, Inc. (Raymond James), RBC Capital Markets, LLC, Scotia Capital (USA) Inc. (Scotia) and SMBC Nikko Securities America, Inc. (SMBC), each as sales agent and/or principal and/or (except in the case of Raymond James, Scotia and SMBC) forward seller (in any such capacity, each an Agent and together the Agents) and Bank of America, N.A., Citibank, N.A., Jefferies LLC,

Cytori Therapeutics Inc – Cytori Therapeutics, Inc. Sales Agreement (June 1st, 2018)
Griffin Land & Nurseries, Inc. – GRIFFIN INDUSTRIAL REALTY, INC. Common Stock ($0.01 Par Value Per Share) Sales Agreement (May 10th, 2018)
Ra Pharmaceuticals, Inc. – RA PHARMACEUTICALS, INC. Common Stock ($0.001 Par Value Per Share) AT-THE- MARKET EQUITY OFFERING SALES AGREEMENT (May 9th, 2018)

Ra Pharmaceuticals, Inc., a Delaware corporation (the Company), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time to or through Stifel, Nicolaus & Company, Incorporated (Stifel Nicolaus), as sales agent and/or principal (Agent), shares (the Shares) of the Companys common stock, $0.001 par value per share (the Common Stock), having an aggregate offering price of up to $50,000,000 on the terms set forth in Section 2 of this At-The-Market Equity Offering Sales Agreement (the Agreement). The Company agrees that whenever it determines to sell Shares directly to the Agent as principal, it will enter into a separate agreement (each, a Terms Agreement) in substantially the form of Annex I hereto, relating to such sale in accordance with Section 3 of this Agreement.

(Par Value $0.001 Per Share) Controlled Equity OfferingSM Sales Agreement (May 9th, 2018)
Isoray – ISORAY, Inc. $8,500,000 cOMMON STOCK SALES AGREEMENT (May 8th, 2018)
AMENDMENT NO. 1 TO At-The-Market Issuance SALES AGREEMENT (May 7th, 2018)

Synthetic Biologics, Inc. (the "Company") and FBR Capital Markets & Co. ("FBR") are parties to that certain At-the-Market Issuance Sales Agreement dated August 5, 2016 (the "Original Agreement"). All capitalized terms not defined herein shall have the meanings ascribed to them in the Original Agreement. The parties, together with B. Riley FBR, Inc. ("B. Riley FBR"), intending to be legally bound, hereby amend the Original Agreement as follows:

Retail Opportunity Investments Partnership, LP – Retail Opportunity Investments Corp. Common Stock ($0.0001 Par Value Per Share) SALES AGREEMENT (May 2nd, 2018)
Retail Opportunity Investments Partnership, LP – Retail Opportunity Investments Corp. Common Stock ($0.0001 Par Value Per Share) SALES AGREEMENT (May 2nd, 2018)
Retail Opportunity Investments Partnership, LP – Retail Opportunity Investments Corp. Common Stock ($0.0001 Par Value Per Share) SALES AGREEMENT (May 2nd, 2018)
Retail Opportunity Investments Partnership, LP – Retail Opportunity Investments Corp. Common Stock ($0.0001 Par Value Per Share) SALES AGREEMENT (May 2nd, 2018)
Lantheus Holdings, Inc. – Amendment No. 1 to Sales Agreement (May 2nd, 2018)

THIS AMENDMENT NO. 1 TO SALES AGREEMENT (this "Amendment") is made effective as of January 1, 2010 by and between NTP Radioisotopes (Pty) Ltd., a commercial company registered and existing under the laws of the Republic of South Africa, having its registered office at Building 1700, Pelindaba, Church Street West Extension, Brits District, North West Province of South Africa ("NTP"), and Lantheus Medical Imaging, Inc., a corporation organized and existing under the laws of Delaware with a place of business at 331 Treble Cove Road, North Billerica, Massachusetts, United States of America 01862 ("Lantheus").

Retail Opportunity Investments Partnership, LP – Retail Opportunity Investments Corp. Common Stock ($0.0001 Par Value Per Share) SALES AGREEMENT (May 2nd, 2018)
Lantheus Holdings, Inc. – Amendment No. 2 to Sales Agreement (May 2nd, 2018)

THIS AMENDMENT NO. 2 TO SALES AGREEMENT (this "Amendment") is made effective as of April 1, 2011 by and between NTP Radioisotopes (Pty) Ltd., a commercial company registered and existing under the laws of the Republic of South Africa, having its registered office at Building 1700, Pelindaba, Church Street West Extension, Brits District, North West Province of South Africa ("NTP"), and Lantheus Medical Imaging, Inc., a corporation organized and existing under the laws of Delaware with a place of business at 331 Treble Cove Road, North Billerica, Massachusetts, United States of America 01862 ("Lantheus").

Lantheus Holdings, Inc. – Amendment No. 3 to Sales Agreement (May 2nd, 2018)

THIS AMENDMENT NO. 3 TO SALES AGREEMENT (this "Amendment") is made effective as of October 1, 2012 by and between NTP Radioisotopes (Pty) Ltd., a commercial company registered and existing under the laws of the Republic of South Africa, having its registered office at Building 1700, Pelindaba, Church Street West Extension, Brits District, North West Province of South Africa ("NTP"), and Lantheus Medical Imaging, Inc., a corporation organized and existing under the laws of Delaware with a place of business at 331 Treble Cove Road, North Billerica, Massachusetts, United States of America 01862 ("Lantheus").

Sales Agreement (April 6th, 2018)

THIS SALES AGREEMENT is made as of October 31, 2017, by and between Canbiola, Inc., a Florida corporation (the Company) and Christy Davies, an individual resident of Utah (the Salesperson).

Crown Castle International Corp. Common Stock ($0.01 Par Value) SALES AGREEMENT (April 6th, 2018)

Crown Castle International Corp., a Delaware corporation (Company), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time to or through [], as sales agent and/or principal (Agent), shares (Shares) of the Companys common stock, $0.01 par value (Common Stock), on the terms set forth in this Sales Agreement. The Company has also entered into separate sales agreements (each, an Alternative Sales Agreement), dated as of the date hereof, with each of [Merrill Lynch, Pierce, Fenner & Smith Incorporated, Barclays Capital Inc., Citigroup Global Markets Inc., Credit Agricole Securities (USA) Inc., Fifth Third Securities, Inc., Jefferies LLC, J.P. Morgan Securities LLC, Mizuho Securities USA LLC, Morgan Stanley & Co. LLC, MUFG Securities Americas Inc., RBC Capital Markets, LLC, SG Americas Securities, LLC, SMBC Nikko Securities America, Inc., SunTrust Robinson Humphrey, Inc., TD Securities (USA) LLC and Wells Fargo Securities, LLC] (each, an Alternative

Myovant Sciences Ltd. – Myovant Sciences Ltd. Common Shares Sales Agreement (April 3rd, 2018)
Senseonics Holdings, Inc. – Senseonics Holdings, Inc. Common Stock Sales Agreement (March 30th, 2018)
Thorium Power – LIGHTBRIDGE CORPORATION Common Stock (Par Value $0.001 Per Share) At-The-Market Issuance Sales Agreement (March 30th, 2018)
Proteostasis Therapeutics, Inc. – Proteostasis Therapeutics, Inc. Common Stock Sales Agreement (March 23rd, 2018)

Proteostasis Therapeutics, Inc., a Delaware corporation (the Company), confirms its agreement (this Agreement) with Leerink Partners LLC (Leerink), as follows:

(Par Value $0.01 Per Share) Controlled Equity OfferingSM Sales Agreement (March 13th, 2018)